Biogen Inc., of Cambridge, Mass., reported full-year revenues totaling $13.5 billion, up 10 percent over 2017, driven primarily by the continued global launch of spinal muscular atrophy drug Spinraza (nusinersen), which contributed $1.7 billion in revenues in 2018 vs. $884 million for the prior year.